Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Uptake of Telehealth in Parkinson’s Disease Clinical Care and Research During COVID-19 Pandemic: a Parkinson Study Group Survey
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
143
To assess the impact of COVID-19 on clinical practice and research visits among active Parkinson Study Group (PSG) clinician members.
Traditionally, medical care & research in Parkinson’s disease have been conducted with in-person encounters. Alternatives such as telephone, video conferencing, wearable devices have been used less frequently. The recent COVID-19 pandemic has profoundly impacted the delivery of in person care and clinical research.
We conducted an online survey using the open-access online SurveyMonkey tool (http://www.surveymonkey.com). The survey had 27 items and was divided into clinical care and research modules. Both modules were designed to elucidate clinical/research care before and during COVID-19. The survey was sent to 414 active PSG members with weekly reminders and it remained accessible for 30 days from May 2020.
We received 142 responses, of which 133 (94%) were complete. The clinical use of virtual visits via synchronous video conferencing increased from 39.5% pre-COVID to 94.6% with 65% of respondents reporting that it was the most preferred method of communication during COVID-19. Institutional preference (83.3%) and HIPAA compliance (68%) were the top reasons for selecting a particular telemedicine platform. Lack of access for patients (76.3%) and patient resistance (60.9%) were the top barriers.

Approximately 70% respondents stated that 75-100% of their research activities were suspended due to COVID-19. Many sites had to fill out protocol deviations (38.2%), protocol exceptions (25.5%) or change their research profile due to layoffs (16.8%). The overall use of video conferencing increased from 30.34% to 64.13% while its use as the most preferred method increased to 40.22%. Most respondents agreed that future studies will use telehealth to a larger extent.
There is an evident need for flexibility in conducting office visits and clinical trials in Parkinson patients. Technology has the potential to enhance patient care & convenience, when in-person visits can be challenging.
Authors/Disclosures
Vikram Shivkumar, MD, FÂ鶹´«Ã½Ó³»­ (Orlando Health)
PRESENTER 		Dr. Shivkumar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific.
Thyagarajan Subramanian, MD, MBBS, FÂ鶹´«Ã½Ó³»­ (University of Toledo) Dr. Subramanian has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Subramanian has received research support from National Institutes of Health. The institution of Dr. Subramanian has received research support from Ann and Phillip Gladfetler III Foundation. The institution of Dr. Subramanian has received research support from Department of Defense . Dr. Subramanian has received publishing royalties from a publication relating to health care. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with National Institutes of Health.
Pinky H. Agarwal, MD, FÂ鶹´«Ã½Ó³»­ (Evergreen Health) Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals Inc. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion Pharmaceuticals. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AskBio. An immediate family member of Dr. Agarwal has stock in ALDEYRA THERAPEUTICS INC. An immediate family member of Dr. Agarwal has stock in Curis Inc. An immediate family member of Dr. Agarwal has stock in Citius Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Fortress Biotech. An immediate family member of Dr. Agarwal has stock in TG Therapeutics. An immediate family member of Dr. Agarwal has stock in ATYR PHARMA INC . An immediate family member of Dr. Agarwal has stock in CORVUS PHARMACEUTICALS INC . An immediate family member of Dr. Agarwal has stock in LAVA THERAPEUTICS . An immediate family member of Dr. Agarwal has stock in OVID THERAPEUTICS INC . An immediate family member of Dr. Agarwal has stock in TERNS PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in VIKING THERAPEUTICS INC. Dr. Agarwal has stock in WAVE LIFE SCIENCES LTD. An immediate family member of Dr. Agarwal has stock in ProQr Therapeutics. An immediate family member of Dr. Agarwal has stock in Mind Medicine. An immediate family member of Dr. Agarwal has stock in Lyra Therapeutics. An immediate family member of Dr. Agarwal has stock in Larimer Therapeutics. An immediate family member of Dr. Agarwal has stock in Lantern Pharma. An immediate family member of Dr. Agarwal has stock in Black Diamond Therapeutics. An immediate family member of Dr. Agarwal has stock in Amylyx Pharma. An immediate family member of Dr. Agarwal has stock in Palisade Bio. An immediate family member of Dr. Agarwal has stock in Inozyme Pharma. An immediate family member of Dr. Agarwal has stock in Pyxis Oncology. An immediate family member of Dr. Agarwal has stock in Vertex Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Vyne Therapeutics. An immediate family member of Dr. Agarwal has stock in Reviva Pharmaceuticals Hld. An immediate family member of Dr. Agarwal has stock in Immuneering Corp. An immediate family member of Dr. Agarwal has stock in Imunon Inc. An immediate family member of Dr. Agarwal has stock in Enlivex Therapeutics. An immediate family member of Dr. Agarwal has stock in Candel Therapeutics. An immediate family member of Dr. Agarwal has stock in Applied Digital Corp. An immediate family member of Dr. Agarwal has stock in Atai Life Sciences. An immediate family member of Dr. Agarwal has stock in Adma Biologics. The institution of Dr. Agarwal has received research support from Biogen . The institution of Dr. Agarwal has received research support from CHDI Foundation. The institution of Dr. Agarwal has received research support from Eli Lilly. The institution of Dr. Agarwal has received research support from MJ Fox. The institution of Dr. Agarwal has received research support from Roche . The institution of Dr. Agarwal has received research support from Supernus. The institution of Dr. Agarwal has received research support from Nova Nordisc. The institution of Dr. Agarwal has received research support from Inhibikase. The institution of Dr. Agarwal has received research support from Intracellular therapeurtics.
Zoltan Mari, MD, FÂ鶹´«Ã½Ó³»­ (Cleveland Clinic Lou Ruro Center for Brain Health) Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Mari has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ACADIA. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Parkinson Study Group. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Dr. Mari has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ACADIA. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for US World Meds. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Moore and Moore PLLC. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Francis Law Firm PLLC. Dr. Mari has stock in NeuroReserve. Dr. Mari has stock in Sensory Cloud. The institution of Dr. Mari has received research support from Cerevel. The institution of Dr. Mari has received research support from AbbVie. The institution of Dr. Mari has received research support from NIH. The institution of Dr. Mari has received research support from Parkinson's Foundation. The institution of Dr. Mari has received research support from Michael J Fox Foundation. The institution of Dr. Mari has received research support from LBDA. The institution of Dr. Mari has received research support from Eli Lilly.
Tiago Mestre, MD, MSC (University of Ottawa) Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CHDI. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Mestre has received research support from CIHR. The institution of Dr. Mestre has received research support from Ontario Research Fund. The institution of Dr. Mestre has received research support from MJFF. The institution of Dr. Mestre has received research support from Parkinson Canada. The institution of Dr. Mestre has received research support from University of Ottawa/PRC.